Is Cidofovir registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Cidofovir, including Cidofovir BOS (75 mg/ml, Concentrate for solution for infusion, SAR 49597.50).

Is Cidofovir approved by the US FDA?

Drugs@FDA lists 3 application product lines for Cidofovir, including CIDOFOVIR (Prescription); CIDOFOVIR (Prescription); VISTIDE (Discontinued).

Is Cidofovir authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Cidofovir.

Active substance

Cidofovir

SFDA 1
US FDA 3
EMA 1
Health Canada 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
Cidofovir BOS	75 mg/ml	Concentrate for solution for infusion · Intravenous use	10 Vial	SAR 49597.50	Generic · Prescription	Boston Oncology Arabia	Valid

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
CIDOFOVIR	EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	solution · intravenous	MYLAN INSTITUTIONAL	Prescription	27 Jun 2012
CIDOFOVIR	EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	solution · intravenous	AVET LIFESCIENCES	Prescription	26 Jul 2012
VISTIDE	EQ 375MG BASE/5ML (EQ 75MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	solution · intravenous	GILEAD SCIENCES INC	Discontinued	26 Jun 1996

EMA European Union — centrally authorised medicines

Vistide Gilead Sciences International Limited · Withdrawn · authorised 23 Apr 1997 · ATC J05AB12

Therapeutic indication (EMA)

Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
MAR-CIDOFOVIR	02473925	375 MG / 5 ML	SOLUTION · INTRAVENOUS	MARCAN PHARMACEUTICALS INC

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.